Stuart Fuchs Joins Provectus Pharmaceuticals's Corporate consultatory Board Benzinga Its medicine drug PH-10 also targets abnormal or diseased cells, with the current focussing on psoriasis and atopic dermatitis. Provectus has lately completed its Phase ii trials of PV-10 As a therapy for pathological process melanoma, and of PH-10 as a ... and more » Link To Article
No comments:
Post a Comment